Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.58 |
| ▸ | CETP | P11597 | 11/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | PTGES | O14684 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CEPT1 | Q9Y6K0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29327603 | 0.92 | PPARG (0.61) | PPARGCETPTP53RXFP1MAPT | |
| SCHEMBL29327683 | 0.89 | PPARG (0.72) | PPARGCETPTP53RXFP1MAPT | |
| SCHEMBL29327677 | 0.87 | PPARG (0.59) | PPARGCETPTP53RXFP1MAPT | |
| SCHEMBL29327840 | 0.85 | PPARG (0.57) | PPARGCETPTP53RXFP1MAPT | |
| SCHEMBL29327701 | 0.85 | PPARG (0.55) | PPARGCETPTP53RXFP1MAPT | |
| SCHEMBL29327713 | 0.83 | PPARG (0.63) | PPARGCETPTP53MAPTSMN1; SMN2 | |
| SCHEMBL29327675 | 0.83 | MAPT (0.55) | PPARGCETPTP53RXFP1MAPT | |
| SCHEMBL29327765 | 0.83 | PPARG (0.57) | PPARGTP53RXFP1MAPTSMN1; SMN2 | |
| SCHEMBL29327696 | 0.82 | TP53 (0.56) | PPARGCETPTP53RXFP1MAPT | |
| SCHEMBL29327687 | 0.82 | PPARG (0.55) | PPARGCETPTP53RXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239760-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239760-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | PPARG 1/4885CETP 715/4885TP53 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.